A long-acting amylin analogue studied for once-weekly appetite and weight-regulation research.
Pre-loaded with a typical Cagrilintide vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Cagrilintide. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 300 mcg – 4.5 mg | once weekly | subcutaneous | Phase 2 monotherapy dose-finding (once-weekly SC) Lau et al. evaluated 0.3–4.5 mg once weekly with stepwise escalation for tolerability. |
| 160 mcg – 4.5 mg | once weekly | subcutaneous | Phase 1b combination with semaglutide Enebo et al. co-escalated cagrilintide 0.16–4.5 mg with semaglutide in a controlled trial setting. |
People searching this page also look for: cagrilintide peptide dosage, cagrilintide peptide dosage chart.
Cagrilintide is a synthetic, fatty-acid–acylated analogue of amylin designed for extended circulating exposure. Amylin is a pancreatic peptide co-secreted with insulin; researchers study cagrilintide because it engages amylin-family receptors involved in satiety signaling, gastric emptying, and energy-intake control. Unlike native amylin, the engineered structure supports once-weekly subcutaneous investigation in clinical research settings.
Interest accelerated after dose-finding and combination studies paired cagrilintide with GLP-1 receptor agonists such as semaglutide (often discussed as CagriSema). Published phase 1–3 programs have evaluated monotherapy and fixed-dose combinations for body-weight and metabolic endpoints under controlled protocols. All material discussed here is framed for research use only.
For laboratory and literature work, cagrilintide is typically handled as a lyophilized peptide or prefilled clinical-trial presentation. Research teams track titration schedules carefully because gastrointestinal tolerability in trials improved when doses were escalated rather than started at the top of the tested range.
Cagrilintide activates amylin receptors (calcitonin receptor paired with receptor activity–modifying proteins). Downstream signaling in brainstem and hypothalamic circuits is associated with reduced food intake and slower gastric emptying in experimental models. Lipidation prolongs albumin binding and extends plasma half-life into a multi-day window, which is why weekly subcutaneous regimens appear in published protocols rather than multiple daily native-amylin dosing.
obesity and weight-regulation research · type 2 diabetes combination studies · amylin receptor pharmacology · GLP-1 co-agonist / dual-incretin stack research · appetite and gastric-emptying physiology
Metabolic disease groups, obesity-pharmacology labs, and clinical trial units studying next-generation weight-management peptides track cagrilintide closely. Formulation and PK teams also use it as a case study in acylated long-acting peptide design. Interest is research-focused; it is not presented here as a consumer therapy.
Lyophilized peptide is typically stored refrigerated or frozen per supplier COA, protected from light and moisture. After reconstitution with bacteriostatic water, research labs generally refrigerate and use within the stability window stated on the lot documentation.
The best-documented research pairing is with semaglutide (CagriSema), combining amylin-pathway and GLP-1-pathway pharmacology. Literature discussions sometimes place it alongside other incretin or nutrient-stimulated hormone analogues when mapping multi-agonist weight-regulation strategies. Stacking references describe controlled trial designs, not informal self-directed protocols.
The questions people actually search for, answered plainly.
Published clinical research most often cites once-weekly subcutaneous doses from about 0.3 mg up to 4.5 mg, frequently after gradual escalation. Combination programs commonly highlight a 2.4 mg weekly anchor dose paired with semaglutide. These figures are documented trial exposures, not personal-use instructions.
Research reconstitution volume depends on vial strength and target concentration. For a 5 mg vial, 2–3 mL bacteriostatic water is a common laboratory starting point so that weekly milligram doses can be measured with an insulin syringe. Always follow the specific COA and protocol math for the lot in use.
Cagrilintide is not typically described as a daily peptide in modern trials. Its long half-life supports once-weekly subcutaneous schedules in the published clinical literature.
Trial publications and protocols outline escalation tables (for example stepping through 0.3 → 0.6 → 1.2 → 2.4 → 4.5 mg weekly). Any chart derived from those papers should be treated as a literature reference tool for research planning only.
Phase 1b pharmacokinetic work reported plasma half-life values of roughly 159–195 hours, consistent with weekly dosing designs.
Yes in the narrow research sense: controlled studies have co-administered cagrilintide with semaglutide. That is a formal dual-agonist research program, not a recommendation to combine research chemicals outside approved studies.
No. It is a long-acting amylin analogue engineered for extended exposure. Pramlintide is a different amylin mimetic with a much shorter clinical dosing cadence.
Independent research-supply listings often show multi-milligram lyophilized vials (commonly discussed around 5–10 mg). Clinical trial product presentations differ and are protocol-specific.
Primary literature on Cagrilintide. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides